Compared with the DCM group, 15 mg/kg Cilostazol and 30 mg/kg Cilostazol could significantly decrease TXNIP, NLRP3, and cleaved Caspase-1 levels (p < 0.05). Here, NLRP3 is linked to familial dilated cardiomyopathy.